IRLAB Therapeutics Investor Relations Material
Latest events
Q2 2025
IRLAB Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from IRLAB Therapeutics
Access all reports
IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IRLAB
Country
🇸🇪 Sweden